453 related articles for article (PubMed ID: 20624322)
1. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
[TBL] [Abstract][Full Text] [Related]
2. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
[TBL] [Abstract][Full Text] [Related]
3. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Shinmura K; Kageyama S; Tao H; Bunai T; Suzuki M; Kamo T; Takamochi K; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
Lung Cancer; 2008 Aug; 61(2):163-9. PubMed ID: 18242762
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
[TBL] [Abstract][Full Text] [Related]
6. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
7. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
8. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
[TBL] [Abstract][Full Text] [Related]
10. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
Li T; Maus MK; Desai SJ; Beckett LA; Stephens C; Huang E; Hsiang J; Zeger G; Danenberg KD; Astrow SH; Gandara DR
J Thorac Oncol; 2014 Jan; 9(1):18-25. PubMed ID: 24346090
[TBL] [Abstract][Full Text] [Related]
11. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Inamura K; Takeuchi K; Togashi Y; Hatano S; Ninomiya H; Motoi N; Mun MY; Sakao Y; Okumura S; Nakagawa K; Soda M; Choi YL; Mano H; Ishikawa Y
Mod Pathol; 2009 Apr; 22(4):508-15. PubMed ID: 19234440
[TBL] [Abstract][Full Text] [Related]
12. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
13. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
Guo Y; Ma J; Lyu X; Liu H; Wei B; Zhao J; Fu S; Ding L; Zhang J
BMC Cancer; 2014 Nov; 14():834. PubMed ID: 25407901
[TBL] [Abstract][Full Text] [Related]
15. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Tanaka H; Hayashi A; Morimoto T; Taima K; Tanaka Y; Shimada M; Kurose A; Takanashi S; Okumura K
BMC Cancer; 2012 Nov; 12():558. PubMed ID: 23181703
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
18. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
Zhao F; Xu M; Lei H; Zhou Z; Wang L; Li P; Zhao J; Hu P
PLoS One; 2015; 10(2):e0117333. PubMed ID: 25706305
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]